#USA #New Orleans #Vector BioMed #LENTIVERSE #Dr. Boro Dropulic

Vector BioMed's Groundbreaking Presentations at ISCT and ASGCT 2025

In May 2025, Vector BioMed (VBM) will be at the forefront of innovation in the gene therapy field, participating in two major industry events: the International Society for Cell and Gene Therapy (ISCT) and the American Society of Gene and Cell Therapy (ASGCT). CEO Dr. Boro Dropulic is set to present on crucial advancements, including the unveiling of the company's new platform, the LENTIVERSE™, aimed at simplifying and enhancing access to gene therapies.

Understanding LENTIVERSE™

VBM's LENTIVERSE™ is not just a platform; it represents a modular ecosystem that seeks to transform the production of lentiviral vectors. This innovation is designed to eliminate obstacles that have historically hindered access to cell and gene therapies. During his presentation at ISCT, Dr. Dropulic will discuss key steps necessary for evolving the gene therapy landscape by focusing on faster vector design and expedited clinical timelines.

According to Dr. Dropulic, "We've reached an inflection point in gene therapy where affordable and innovative vector production is crucial for moving seamless transitions from laboratory to market." The LENTIVERSE™ embodies this sentiment of efficiency with the intent of supporting developers in the cell and gene therapy (CGT) space.

Key Highlights from ISCT

At the ISCT conference, attendees will have the opportunity to hear Dr. Dropulic speak about the future of lentiviral manufacturing at a session titled "The Next Frontier in Lentiviral Manufacturing" on May 8, 2025. The presentation scheduled from 6:30 to 6:45 PM CT at the Global Showcase Theater A will dive into how decentralized manufacturing and advanced lentiviral design can tackle long-standing issues in the gene therapy sector. These include high costs and complex processes that limit patient access worldwide. Vector BioMed will also showcase its innovative products at booth 937 during the conference.

ASGCT Conference Presence

Following ISCT, VBM will exhibit at the ASGCT event from May 13 to 17 at the New Orleans Ernest N. Morial Convention Center. Positioned at booth 1348, VBM invites attendees to learn about their cutting-edge LENTIVERSE™ platform and its potential impact on the landscape of viral vector innovation. The exhibition will focus on how VBM is reshaping the approach to viral vector production, enhancing accessibility to vital therapies and effectively revolutionizing patient outcomes in gene therapy.

About Vector BioMed

Vector BioMed is a public benefit corporation dedicated to reimagining lentiviral vector manufacturing. Emanating from the non-profit Caring Cross, VBM aims to provide accessible, affordable gene therapies, supporting various stakeholders such as biotech startups and global health systems. They offer customizable and readily available vector solutions that bridge the gap between innovative research and concrete cures.

As these events approach, industry stakeholders are eager to see how Vector BioMed’s initiatives will unfold, transforming the current landscape of gene therapy with pioneering technologies and streamlined processes. By prioritizing accessibility and efficiency, VBM is set to drive significant advancements and inspire further innovation in this critical field.

For media inquiries, please reach out to Bryce Goodman, Director of Marketing and Communications at Vector BioMed.

Email: [email protected] | Mobile: 440-315-1796.